Biomerica Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Biomerica Inc (BMRA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Biomerica Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4M vs 62,157M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-21.3% annualized vs trailing 12 months), vs accelerating (+3.5%) for its tracked peer group.
- Growth: Biomerica Inc generated 17.0% revenue growth year over year in Q4 2026, vs 10.0% for its tracked competitors combined.
- Profitability: Its -130.7% net margin compares with 12.6% for the peer group.
- Scale: Biomerica Inc ranks #14 of 19 companies by market capitalization in the In Vitro & In Vivo Diagnostic Substances industry, holding 0.0% of industry market cap.
- Peer revenue share: Biomerica Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.09M compares with $0.35M for the peer group (0.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BMRA Sales vs. its Competitors, Q4 2026
Biomerica Inc reported revenue growth of 16.96 % year on year in Q4 2026, above its competitors' combined revenue growth of 10.03 %.
With a net margin of -130.71 %, Biomerica Inc reported lower profitability than its competitors (12.56 %).
Biomerica Inc generated 0.01 % of the combined sales of its peer group, up from 0.01 % a year earlier.
Biomerica Inc vs. its Competitors, Q4 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Biomerica Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Biomerica Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Biomerica Inc's competitor groups requires a Commercial License.
For context: the In Vitro & In Vivo Diagnostic Substances industry grew revenue 2.5% year over year, combined, vs 17.0% for Biomerica Inc. Biomerica Inc's share of combined industry revenue moved from 0.02% to 0.03%, a gain of 0.00 percentage points.
Biomerica Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Biomerica Inc | No | No | No | No |
| Competitors combined (8) | ||||
| Similar-Size Competitors (9) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 25.00 % (2 of 8) | 25.00 % (2 of 8) | 14.30 % (1 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BMRA Stock Performance relative to its Competitors
BMRA Stock Performance relative to Similar-Size Competitors
BMRA Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Caredx Inc | 282.9% | Outperformed |
| 2 | Thermo Fisher Scientific Inc | 282.9% | Outperformed |
| 3 | Quest Diagnostics Inc | 282.9% | Outperformed |
| 4 | Hologic Inc | 282.9% | Outperformed |
| 5 | Fulgent Genetics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Biomerica Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Biomerica Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Biomerica Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Biomerica Inc | 6.97 | 4.45 |
| Thermo Fisher Scientific Inc | 251,760.60 | 46,336.00 |
| Abbott Laboratories | 176,419.43 | 45,134.00 |
| Quest Diagnostics Inc | 26,613.44 | 11,560.00 |
| Hologic Inc | 17,087.75 | 3,644.80 |
| Caredx Inc | 3,451.09 | 458.09 |
| SUBTOTAL | 477,107.11 | 110,940.42 |
Sign in to see all competitors of Biomerica Inc .
Sources: Biomerica Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Biomerica Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Biomerica Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Thermo Fisher Scientific Inc | Clinical Research 19.98 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
| Quest Diagnostics Inc | Diagnostic Information Services Business 97.86 % |
| Hologic Inc | Diagnostics 51.18 % |
| Caredx Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Biomerica Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Biomerica Inc | 7 | 89,060 | -75,500 |
| Thermo Fisher Scientific Inc | 251,761 | 370,688 | 55,912 |
| Abbott Laboratories | 176,419 | 392,470 | 54,574 |
| Quest Diagnostics Inc | 26,613 | 202,807 | 19,526 |
| Hologic Inc | 17,088 | 515,530 | 76,917 |
| Caredx Inc | 3,451 | 598,809 | 145,114 |
| PEERS TOTAL | 477,100 | 351,754 | 43,714 |
Biomerica Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Biomerica Inc | Europe 29.08 % |
| Thermo Fisher Scientific Inc | North America 51.27 % |
| Abbott Laboratories | Non-US 61.62 % |
| Hologic Inc | Non-US 30.23 % |
| Caredx Inc | United States 96.56 % |
| Fulgent Genetics Inc | Other countries 4.93 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Biomerica Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 18 companies in Biomerica Inc's industry classification, broader than the peer set above. Market cap in millions of $.Biomerica Inc ranks #14 of 18 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 5,329, indicating a highly concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Idexx Laboratories Inc | 41,147 | 71.65 % |
| 2 | Lantheus Holdings Inc | 6,749 | 11.75 % |
| 3 | Neogen Corporation | 3,010 | 5.24 % |
| 4 | Celldex Therapeutics inc | 2,387 | 4.16 % |
| 5 | Intellia Therapeutics Inc | 1,234 | 5.2% |
| 6 | Quidelortho Corp | 1,234 | 5.2% |
| 7 | Achieve Life Sciences Inc | 1,234 | 5.2% |
| 8 | Alpha Teknova Inc | 1,234 | 5.2% |
| 9 | Myriad Genetics Inc | 1,234 | 5.2% |
| 10 | Insight Molecular Diagnostics Inc | 1,234 | 5.2% |
| 14 | Biomerica Inc | 7 | 0.01 % |
Market cap and industry share for the rest of Biomerica Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-25.
Biomerica Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 9 | Myriad Genetics Inc | 392 | -46.65 % |
| 10 | Insight Molecular Diagnostics Inc | 137 | 14.42 % |
| 11 | Immucell Corporation | 90 | 61.65 % |
| 12 | Aspira Women s Health inc | 12 | -55.71 % |
| 13 | Qc Technologies Inc | 1,234 | 12.3% |
| 14 | Biomerica Inc | 7 | -17.52 % |
| 15 | Cardio Diagnostics Holdings Inc | 1,234 | 12.3% |
| 16 | Volitionrx Limited | 1,234 | 12.3% |
| 17 | Trinity Biotech Plc | 1,234 | 12.3% |
| 18 | Burzynski Research Institute Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Biomerica Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Biomerica Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the In Vitro & In Vivo Diagnostic Substances industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (18 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 8.13 % | 37.70 % (avg) | -29.6 pp |
| Operating Margin | -119.47 % | industry median | -88.6 pp |
| EBITDA Margin | -80.87 % | -15.74 % (avg) | -65.1 pp |
| Capital Intensity (Capex / Revenue) | - | 4.23 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Biomerica Inc's Valuation vs Competitive Position
Valuation multiples vs the In Vitro & In Vivo Diagnostic Substances industry average (18 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 52.0x | - |
| EV / EBITDA | - | 16.5x | - |
| P/B | 1.5x | 4.6x | -3.1x |
| Return on Equity | -99.30 % | industry aggregate | -95.92 % |
| Return on Invested Capital | -66.15 % | 0.79 % (avg) | -66.94 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Biomerica Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -88.35 % | -86.62 % | -133.09 % | - | 500.00 % | -65.80 % | 1.42 % | -20.08 % |
| Operating Margin | -14.36 % | -58.53 % | 263.48 % | -470.90 % | -34.82 % | -115.04 % | -105.56 % | -118.15 % |
| Return on Invested Capital | -0.47 % | -3.14 % | -28.57 % | -53.13 % | -31.41 % | -32.17 % | -43.21 % | -55.16 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Biomerica Inc's Strategic Group Map
Every company in Biomerica Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Biomerica Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Biomerica Inc's BCG Growth-Share Matrix
Relative market share (vs Biomerica Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Biomerica Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue -1.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Idexx Laboratories Inc alone holds 72% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Biomerica Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 5,329 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Biomerica Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Biomerica Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Biomerica Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Biomerica Inc falls in the Medium attractiveness / Low strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Biomerica Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 88.6 points below the industry median.
- Return on equity 95.9 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-21.3% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
- Industry dominated by Idexx Laboratories Inc, holding 71.65 % of industry market cap.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Biomerica Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Biomerica Inc | 1.08 | 2.53 | - |
| Thermo Fisher Scientific Inc | 0.32 | 1.62 | 0.78 |
| Abbott Laboratories | 0.47 | 1.60 | 0.35 |
| Quest Diagnostics Inc | 0.22 | 1.22 | 0.76 |
| Hologic Inc | 1.88 | 3.64 | 0.51 |
| Caredx Inc | 1.68 | 3.47 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Biomerica Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Biomerica Inc | Q2 2026 | +17.0 % | - |
| Thermo Fisher Scientific Inc | Q2 2026 | +10.5 % | +7.6 % |
| Abbott Laboratories | Q1 2026 | +7.8 % | -18.7 % |
| Quest Diagnostics Inc | Q2 2026 | +10.2 % | +12.8 % |
| Hologic Inc | Q4 2025 | +44.8 % | -10.9 % |
| Caredx Inc | Q2 2026 | +52.2 % | - |
| PEERS TOTAL | +10.0 % | +15.9 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Biomerica Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Biomerica Inc | Q2 2026 | -5.1 % | - |
| Thermo Fisher Scientific Inc | Q2 2026 | +142.5 % | +53.1 % |
| Abbott Laboratories | Q1 2026 | +9.4 % | -17.6 % |
| Quest Diagnostics Inc | Q2 2026 | +10.9 % | +27.8 % |
| Hologic Inc | Q4 2025 | -18.1 % | -54.3 % |
| Caredx Inc | Q2 2026 | - | - |
Biomerica Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Biomerica Inc | - | - | - |
| Thermo Fisher Scientific Inc | 6.36% | 7.71% | 13.37% |
| Abbott Laboratories | 6.87% | 8.15% | 12.09% |
| Quest Diagnostics Inc | 6.74% | 8.05% | 14.85% |
| Hologic Inc | 6.12% | 7.26% | 11.01% |
| Caredx Inc | 24.81% | 29.42% | 32.81% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Biomerica Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Biomerica Inc | - | 1.56 |
| Thermo Fisher Scientific Inc | 36.52 | 5.43 |
| Abbott Laboratories | 28.13 | 3.91 |
| Quest Diagnostics Inc | 25.17 | 2.30 |
| Hologic Inc | 31.65 | 4.69 |
| Caredx Inc | 31.21 | 7.53 |
| PEERS AVERAGE | 34.62 | 4.30 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.